SecBot SecBot

DTIL

PRECISION BIOSCIENCES INC
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001357874 Biotech & Drug Discovery
$6.41 −0.23 (−3.46%)
Oct 26 4:00 PM ET · prev $6.64
Market cap
$187.1M
Micro cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$20.00
+212% · range $18.00–60.00
Next earnings
Nov 2
in 7 days · EPS est. −$0.89
1 year
−10.7%
from $7.18 · Oct 27
30 days
+2.7%
from $6.24
52-week range
$3.57–9.28
−31% from high · low Feb 5
Avg volume 20D
239.9K
shares / day
Short interest
2.51M
≈9.1% of shares · +13.1%
Days to cover
8.8
at average volume
Insider net
+$29.5K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 2 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 2, 2026
Strongest BULLISH Precision BioSciences dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial evaluating…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $29.5K at an average $6.22. No open-market sales.

  • InstitutionsBULLISH

    Q2 2026: 17 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.610 → −$0.890 over 90 days. 1 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +13.1% to 2.51M shares. 8.8 days to cover, ≈9.1% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,172,873$9.2M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED620,981$4.9M
STATE STREET CORPDOUBLED427,325$3.4M
Corient Private Wealth LPADD245,058$1.9M
NORTHERN TRUST CORPDOUBLED190,188$1.5M
JPMORGAN CHASE & CODOUBLED180,452$1.4M
GOLDMAN SACHS GROUP INCDOUBLED139,828$1.1M
Squarepoint Ops LLCDOUBLED137,106$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy5Buy5Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +212%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 3, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 9, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 9, 2026Oppenheimer
INITIATE
INITIATEOutperform
May 27, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$29.5K
bought · 3 insiders
$0
sold · 0 insiders
+3.1%
vs their $6.22 cost
DateInsiderTypeValue
Sep 28, 2026
Frankel Stanley
Director
BUY$6.0K
Sep 25, 2026
Germano Geno J
Director
BUY$16.4K
Sep 25, 2026
Brown Melinda
Director
BUY$7.1K
Jun 3, 2026
Brown Melinda
Director
AWARD20,979 sh
Jun 3, 2026
Buehler Kevin
Director
AWARD20,979 sh
Jun 3, 2026
Pire Shari Lisa
Director
AWARD20,979 sh
Jun 3, 2026
Frankel Stanley
Director
AWARD20,979 sh
Jun 3, 2026
Germano Geno J
Director
AWARD20,979 sh

Earnings setup

Estimates
Nov 2
reports in 7 days
−$0.89
EPS estimate, this quarter
−46%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.89-$1.19–-$0.63-37.6%$1.4M
Next Q-$0.98-$1.26–-$0.47-112.3%$1.3M
Current FY-$3.87-$4.43–-$3.03-55.5%$13.5M
Next FY-$1.86-$2.17–-$1.55+1.8%$8.9M

Short side

FINRA· Sep 30, 2026
2,514,044
shares short
+13.1%
vs prior settlement
8.8
days to cover
≈9.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 Insider
Frankel Stanley bought 1,000 shares
Director @ $6.00 ($6.0K)
Sep 25, 2026 Insider
Germano Geno J bought 2,609 shares
Director @ $6.28 ($16.4K)
Sep 25, 2026 Insider
Brown Melinda bought 1,135 shares
Director @ $6.27 ($7.1K)
Sep 22, 2026 SEC
In Q2 2026, 17 institutional buyers accumulated $15.7M net in Precision Biosciences (DTIL), overwhelmingly driven by…
INST-CLUSTER — Impact 3/10
Aug 24, 2026 SEC
Precision BioSciences dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for…
8-K — Impact 7/10
Aug 6, 2026 SEC
Precision BioSciences reported Q2 2026 results with no revenue and a GAAP net loss of $32.7M ($1.26/share), a wider…
8-K — Impact 7/10
Aug 5, 2026 Earnings calendar
DTIL Q2 2026 Earnings Scheduled — 2026-08-05
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
1,172,873 shares ($9.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 2, 2026
Earnings date
DTIL Q3 2026 Earnings Scheduled — 2026-11-02
Recent
Aug 5, 2026
Earnings date
DTIL Q2 2026 Earnings Scheduled — 2026-08-05
Jul 31, 2026
Short interest
Short Interest: DTIL up 21% to 2.9M shares
Settlement 2026-07-31 | Days to cover: 10.48 | ≈10.43% of shares outstanding (est.)
May 13, 2026
Earnings date
DTIL Q1 2026 Earnings Scheduled — 2026-05-13

SecBot reports

11 filings · 3 bullish · 0 bearish · 8 neutral
All DTIL filing & press-release reports (11)